BGB-11417-102 (NCT04883957) is a Phase 1 trial of sonrotoclax in adult patients with mature B-cell malignancies.
Reading
28 May 2025
Disease State: Small lymphocytic lymphoma
Reading
BGB-11417-101 (NCT04277637) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of sonrotoclax in patients with mature B-cell malignancies.
Reading
28 May 2025
BGB-3111-215 (NCT04116437) is a Phase 2, multicenter, single-arm trial of zanubrutinib in patients with previously treated B-cell lymphoma intolerant of prior treatment with ibrutinib and/or acalabrutinib.
Reading
28 May 2025
ALPINE (NCT03734016) is a global, Phase 3, randomized trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Reading
28 May 2025
SEQUOIA (NCT03336333) is a global Phase 3, open-label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Reading
28 May 2025
